Equivalence of differential operators with a regular singular point

Functional Analysis and Its Applications -     

Magnetic susceptibility and order parameter of the spin-glass-like phase of the double-exchange model

The magnetic susceptibility and Edwards-Anderson order parameter q of the spin-glass-like (SGL) phase of the double-exchange model are evaluated in the weak-coupling or RKKY limit. Dynamical mean-field theory is used to show that q = M(T/T(SGL))2, where M is the classical Brillouin function and T(SGL) is the SGL transition temperature. The correlation length of the SGL phase is determined by a correlation parameter Q that maximizes T(SGL) and minimizes the free energy. The magnetic susceptibility has a cusp at T(SGL) and reaches a nonzero value as T --> 0.     

Schmidt’s game on fractals

We construct (α, β) and α-winning sets in the sense of Schmidt’s game, played on the support of certain measures (absolutely friendly) and show how to compute the Hausdorff dimension for some. In particular, we prove that if K is the attractor of an irreducible finite family of contracting similarity maps of ℝ ^N satisfying the open set condition, (the Cantor’s ternary set, Koch’s curve and Sierpinski’s gasket to name a few known examples), then for any countable collection of non-singular affine transformations, Δ _i : ℝ ^N → ℝ ^N ,

Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data

The A3 adenosine receptor (A3AR) is overexpressed in pathological human cells. Piclidenoson and namodenoson are A3AR agonists with high affinity and selectivity to A3AR. Both induce apoptosis of cancer and inflammatory cells via a molecular mechanism entailing deregulation of the Wnt and the NF-κB signaling pathways. Our company conducted phase I studies showing the safety of these 2 molecules. In the phase II studies in psoriasis patients, piclidenoson was safe and demonstrated efficacy manifested in significant improvements in skin lesions. Namodenoson is currently being developed to treat liver cancer, where prolonged overall survival was observed in patients with advanced liver disease and a Child–Pugh B score of 7. A pivotal phase III study in this patient population has been approved by the FDA and the EMA and is currently underway. Namodenoson is also being developed to treat non-alcoholic steatohepatitis (NASH). A Phase IIa study has been successfully concluded and showed that namodenoson has anti-inflammatory, anti-fibrosis, and anti-steatosis effects. A phase IIb study in NASH is currently enrolling patients. In conclusion, A3AR agonists are promising drug candidates in advanced stages of clinical development and demonstrate safety and efficacy in their targeted indications.